Duloxetine Capsule, Delayed Release
Product Images NDC 68071-3766

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3766). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3766 9)

Duloxetine 30 mg delayed-release capsules label from NuCare Pharmaceuticals, Inc. The label indicates a 90-count package with each capsule containing 33.7 mg Duloxetine Hydrochloride USP equivalent to 30 mg Duloxetine. The label includes manufacturer details, barcode, lot number, expiration date, and storage instructions at 68-77°F. The product is for prescription use only.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A line graph showing the proportion of patients with relapse over time from randomization to relapse in days. Two treatment groups are compared: Placebo (dashed line) and Duloxetine (solid line). The y-axis represents the proportion of patients with relapse from 0 to 1, and the x-axis covers time from 0 to about 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two data series: placebo and duloxetine 60/120 mg once daily, with the duloxetine group consistently having a higher percentage of patient improvement across the pain improvement scale.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time, from randomization to relapse (days), between placebo and duloxetine treatment groups. The x-axis measures days up to 300, and the y-axis shows the proportion of patients with relapse from 0 to 1. The duloxetine group shows a lower proportion of relapse over time compared to placebo.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, illustrating how patient improvement varies across these treatments at different pain improvement thresholds.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The graph shows patients' pain improvement percentages declining from near 70% at low pain improvement to below 10% at 100% pain improvement for all groups, with Duloxetine groups consistently higher than placebo across the pain improvement spectrum.*

FDA Label Image

Figure5 (Duloxetine Fig5)

Line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo. The vertical axis represents percentage of patients improved, and the horizontal axis represents percent improvement in pain from baseline.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The graph shows a higher percentage of patient improvement in the duloxetine groups compared to placebo across different pain improvement levels.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline. Two lines represent Duloxetine 60 mg once daily and placebo groups, with the Duloxetine group showing higher percentages of improvement across various pain improvement thresholds.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The vertical axis shows percentage of patients improved, and the horizontal axis shows percent improvement in pain from baseline. Duloxetine shows a higher percentage of patients improved at lower to mid-range pain improvement levels compared to placebo.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line chart comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF). Two lines are shown: placebo (dashed line with x markers) and Duloxetine 60 mg once daily (solid line with diamond markers). The graph shows higher patient improvement percentages with Duloxetine across pain improvement levels from >0% to 100%.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine hydrochloride, showing the molecular arrangement including a naphthalene ring, thiophene ring, and amine hydrochloride group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.